Narrow Your Results

Novartis’ proprietary anti-VEGF agent RTH258 (brolucizumab) appears to be noninferior to aflibercept for treatment of neovascular age-related macular degeneration (AMD), according to results from 2 ongoing phase 3 studies.

Investigators assessed the time required to detect statistically significant visual field (VF) progression on standard automated perimetry (SAP) after comparing various frequencies of testing.

Immunomodulatory therapy can be an effective steroid-sparing alternative for treating pediatric intermediate uveitis, according to this retrospective study.

This retrospective, longitudinal study assessed the rate of ophthalmic examinations among youths with diabetes, specifically to monitor screening for diabetic retinopathy (DR).

Investigators compared features and outcomes of open-globe repair based on the choice of anesthesia: regional block with monitored anesthesia care or general anesthesia.

Investigators from a single tertiary eye center found that adding dexamethasone to initial antibiotic therapy may reduce hospital stay duration without inducing serious complications.

A novel, disposable contact lens may effectively slow the progression of myopia in children, according to strong results from a 3-year trial.

This prospective, comparative study looked at visual, refractive, aberrometric and contrast sensitivity outcomes after small incision lenticule extraction (SMILE) and wavefront-guided LASIK.

Preliminary results from an extension study of the phase 2 TANZANITE trial show continued benefits of a proprietary triamcinolone acetonide formulation when used as an adjunct to aflibercept for treatment of macular edema associated with retinal vein occlusion.

Six patients have successfully undergone an experimental vitreoretinal surgery with the assistance of a robot, marking the first use of this procedure inside a living human eye.

Whether you plan to take the Demonstration of Ophthalmic Cognitive Knowledge (DOCK) exam or participate in the new ABO Quarterly Questions pilot program, the Academy has the tools you'll need to ensure success.

German medical device company Implandata has received CE Marking for EyeMate, the first approved IOP-monitoring system to offer 24-hour pressure measurements in patients with primary open-angle glaucoma (POAG).

This retrospective study compared outcomes of conventional strabismus surgery with botulinum toxin injections for treatment of acute-onset comitant esotropia in children aged 2 to 10 years.

A small study published in Nature Methods has found that the CRISPR-Cas9 gene editing technique may insert hundreds of unexpected mutations into the genome.

Nicox, the French-based drugmaker, has announced FDA approval for its new topical ocular formulation of cetirizine (Zerviate) to treat ocular itching associated with allergic conjunctivitis.

Biotech startup TearClear has raised $4.5 million to develop their filter technology, which is designed to provide preservative-free delivery of topical medications.

Investigators have developed a new formula based on angle-to-angle (ATA) depth to predict postoperative anterior chamber depth and potentially improve the accuracy of IOL power selection.

Genentech today announced the approval of tocilizumab (Actemra) for the treatment of giant cell arteritis (GCA) in adults.

In this multicenter randomized trial, teprotumumab was more effective than placebo in reducing clinical activity and proptosis in patients with active thyroid-associated ophthalmopathy.

This prospective case series investigated the utility of 3 imaging modalities for assessing the post-CXL demarcation line in vivo.

Findings from a small case series suggest that ocular surface pyogenic granulomas (PGs) may be resolved with topical timolol treatment, and causes fewer adverse effects than conventional treatments.

A cross-sectional study of individuals over 60 from Alabama found a 25% rate of undiagnosed macular degeneration.

Shire has continued to pull strong profits following the launch of their dry eye drug lifitegrast (Xiidra) in August 2016.

New population-based data from a single county in Minnesota have revealed an increased incidence of idiopathic intracranial hypertension (IIH) in the last 2 decades, and it is highly correlated with the rise in obesity during the same period.

This 10-year retrospective study found comparable endothelial cell density (ECD) loss with Descemet stripping endothelial keratoplasty (DSEK) and penetrating keratoplasty (PK).